Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free BLGO Stock Alerts

BioLargo (BLGO) Financials

BioLargo logo
$0.11 -0.01 (-5.26%)
As of 07/17/2026 03:36 PM Eastern
Compare
Annual Income Statements for BioLargo

Annual Income Statements for BioLargo

This table shows BioLargo's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.06 -7.84 -9.12 -10 -11 -8.43 -7.08 -4.47 -3.50 -2.40 -12
Consolidated Net Income / (Loss)		 -5.08 -8.07 -9.55 -11 -11 -9.70 -6.89 -5.13 -4.65 -4.35 -15
Net Income / (Loss) Continuing Operations		 -5.08 -8.07 -10 -9.45 -11 -9.70 -6.89 -5.13 -4.65 -4.36 -15
Total Pre-Tax Income 		-5.08 -8.07 -10 -9.53 -12 -9.81 -6.89 -5.20 -4.65 -4.35 -15
Total Operating Income		 -4.18 -4.93 -5.90 -6.41 -6.70 -7.58 -6.78 -5.39 -4.58 -4.33 -15
Total Gross Profit		 0.07 0.18 0.19 1.24 0.92 1.23 1.10 2.86 6.15 7.85 3.41
Total Revenue		 0.13 0.28 0.52 2.73 1.86 2.43 2.53 5.88 12 18 7.77
Operating Revenue		 0.13 0.28 0.52 2.73 1.86 2.43 2.53 5.88 12 18 7.77
Total Cost of Revenue		 0.06 0.11 0.96 1.49 0.95 1.20 1.43 3.03 6.08 9.93 4.36
Operating Cost of Revenue		 0.06 0.11 0.96 1.49 0.95 1.20 1.43 3.03 6.08 9.93 4.36
Total Operating Expenses		 4.25 5.11 6.09 6.41 7.61 8.81 7.88 8.25 11 12 18
Selling, General & Admin Expense		 3.55 3.71 4.43 5.31 6.14 7.47 6.17 6.73 8.06 9.30 12
Research & Development Expense		 0.68 1.38 1.63 1.72 1.47 1.34 1.37 1.32 2.28 2.88 2.59
Other Operating Expenses / (Income)		 - - - 0.62 - - - - - 0.00 3.89
Impairment Charge		 - - - - - - 0.34 0.20 0.39 0.00 0.01
Total Other Income / (Expense), net		 -0.90 -3.14 -3.72 -4.36 -4.81 -2.23 -0.12 0.20 -0.07 -0.02 -0.33
Interest Expense		 0.99 3.13 3.86 4.52 5.03 2.37 0.23 0.05 - 0.07 0.54
Interest & Investment Income		 - - - - - - - - -0.09 0.04 0.20
Other Income / (Expense), net		 0.10 -0.01 0.14 0.16 0.22 0.14 0.12 0.25 0.02 0.02 0.01
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.02 -0.23 -0.43 -0.48 -0.75 -1.27 0.19 -0.66 -1.14 -1.95 -3.41
Basic Earnings per Share		 ($0.06) ($0.09) ($0.10) ($0.09) ($0.08) ($0.05) ($0.03) ($0.02) ($0.01) ($0.01) ($0.04)
Weighted Average Basic Shares Outstanding		 84.11M 87.94M 98.94M 122.00M 152.09M 195.99M 247.20M 268.30M 285.96M 298.12M 306.95M
Weighted Average Diluted Shares Outstanding		 86.27M 94.95M 105.11M 143.10M 172.34M 238.78M 262.72M 283.19M 295.55M 301.30M 319.75M
Weighted Average Basic & Diluted Shares Outstanding		 86.27M 94.95M 105.11M 143.10M 172.34M 238.78M 262.72M 283.19M 295.55M 301.30M 319.75M

Quarterly Income Statements for BioLargo

This table shows BioLargo's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.20 -0.73 -0.41 -0.44 -0.54 -1.01 -1.16 -1.19 -6.48 -2.95 -2.29
Consolidated Net Income / (Loss)		 -1.51 -1.02 -0.78 -0.78 -1.06 -1.73 -1.92 -1.88 -7.24 -4.14 -3.41
Net Income / (Loss) Continuing Operations		 -1.51 -1.02 -0.78 -0.78 -1.06 -1.75 -1.92 -1.88 -7.31 -4.08 -3.41
Total Pre-Tax Income 		-1.55 -1.03 -0.78 -0.78 -1.06 -1.73 -1.92 -1.88 -7.24 -4.14 -3.41
Total Operating Income		 -1.54 -1.01 -0.76 -0.89 -1.06 -1.62 -1.86 -1.80 -7.18 -4.01 -3.20
Total Gross Profit		 1.44 2.09 2.25 2.14 1.72 1.75 1.49 1.42 0.37 0.13 0.46
Total Revenue		 2.67 4.37 4.76 5.01 4.35 3.65 3.27 2.78 1.10 0.62 1.12
Operating Revenue		 2.67 4.37 4.76 5.01 4.35 3.65 3.27 2.78 1.10 0.62 1.12
Total Cost of Revenue		 1.24 2.28 2.51 2.88 2.63 1.91 1.78 1.36 0.73 0.49 0.66
Operating Cost of Revenue		 1.24 2.28 2.51 2.88 2.63 1.91 1.78 1.36 0.73 0.49 0.66
Total Operating Expenses		 2.97 3.10 3.01 3.03 2.78 3.37 3.35 3.22 7.55 4.14 3.66
Selling, General & Admin Expense		 2.28 2.27 2.23 2.40 2.09 2.58 2.52 2.69 3.09 3.43 2.76
Research & Development Expense		 0.69 0.44 0.78 0.62 0.69 0.79 0.79 0.54 0.62 0.65 0.91
Other Operating Expenses / (Income)		 - - - - 0.00 - 0.04 - 3.85 - 0.00
Total Other Income / (Expense), net		 -0.01 -0.03 -0.01 0.11 0.00 -0.12 -0.06 -0.08 -0.06 -0.13 -0.20
Interest Expense		 - - - - 0.01 - 0.09 - 0.14 - 0.19
Interest & Investment Income		 -0.01 - -0.01 -0.00 0.01 0.04 0.03 -0.08 0.08 0.27 0.07
Other Income / (Expense), net		 0.00 -0.01 0.00 0.11 0.00 -0.10 0.01 0.00 0.00 - -0.09
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.31 -0.29 -0.37 -0.34 -0.52 -0.72 -0.77 -0.69 -0.77 -1.19 -1.12
Basic Earnings per Share		 $0.00 - $0.00 $0.00 $0.00 ($0.01) $0.00 $0.00 ($0.02) ($0.01) ($0.01)
Weighted Average Basic Shares Outstanding		 287.94M 285.96M 294.31M 296.44M 300.49M 298.12M 301.27M 303.20M 308.97M 306.95M 318.70M
Weighted Average Diluted Shares Outstanding		 289.50M 295.55M 296.84M 300.62M 301.18M 301.30M 302.84M 308.99M 313.76M 319.75M 320.88M
Weighted Average Basic & Diluted Shares Outstanding		 289.50M 295.55M 296.84M 300.62M 301.18M 301.30M 302.84M 308.99M 313.76M 319.75M 320.88M

Annual Cash Flow Statements for BioLargo

This table details how cash moves in and out of BioLargo's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.61 0.15 -0.92 -0.34 0.29 0.06 0.25 0.89 2.49 -2.13 -0.18
Net Cash From Operating Activities		 -1.88 -3.72 -4.28 -3.89 -4.42 -4.15 -3.94 -2.76 -2.37 -3.21 -8.30
Net Cash From Continuing Operating Activities		 -1.88 -3.72 -4.89 -3.89 -4.44 -4.15 -3.94 -2.76 -2.37 -3.21 -8.30
Net Income / (Loss) Continuing Operations		 -5.08 -8.07 -9.55 -11 -11 -9.70 -6.89 -5.13 -4.65 -4.35 -15
Consolidated Net Income / (Loss)		 -5.08 -8.07 -9.55 -11 -11 -9.70 -6.89 -5.13 -4.65 -4.35 -15
Depreciation Expense		 0.01 0.02 0.03 0.05 0.07 0.06 0.02 0.05 0.10 0.16 0.15
Amortization Expense		 0.81 2.61 3.06 2.77 3.38 1.62 0.12 0.02 0.17 0.10 0.46
Non-Cash Adjustments To Reconcile Net Income		 2.50 1.92 2.21 3.82 3.55 3.80 2.57 2.56 2.93 2.42 7.29
Changes in Operating Assets and Liabilities, net		 -0.13 -0.19 -0.04 0.17 0.01 0.07 0.25 -0.25 -0.92 -1.54 -1.00
Net Cash From Investing Activities		 0.00 -0.06 -0.03 -0.06 -0.04 -0.12 -0.03 -0.27 -0.48 -1.32 0.44
Net Cash From Continuing Investing Activities		 0.00 -0.06 -0.03 -0.06 -0.04 -0.12 -0.03 -0.27 -0.48 -1.32 0.44
Purchase of Property, Plant & Equipment		 0.00 -0.06 -0.03 -0.06 -0.04 -0.02 -0.02 -0.27 -0.48 -1.24 -0.05
Sale of Property, Plant & Equipment		 - - - - - - - - - 0.00 0.48
Other Investing Activities, net		 - - - - - - - - 0.00 -0.08 0.00
Net Cash From Financing Activities		 3.53 3.97 3.37 3.64 4.47 4.34 4.23 3.96 4.66 4.44 8.22
Net Cash From Continuing Financing Activities		 3.53 3.97 3.37 3.64 4.76 4.34 4.23 3.96 5.46 2.39 7.69
Repayment of Debt		 -0.02 0.00 -0.05 -0.24 -1.09 -0.06 -0.87 -0.03 0.04 -0.01 0.02
Issuance of Debt		 0.00 0.80 0.25 0.83 0.83 0.77 0.00 0.10 0.00 0.86 1.26
Issuance of Preferred Equity		 - - - - - - 0.00 0.23 1.58 0.00 2.15
Issuance of Common Equity		 0.75 0.00 1.26 1.84 0.13 3.63 4.93 3.62 2.15 0.59 2.03
Other Financing Activities, net		 2.80 3.17 1.95 1.21 4.90 0.00 0.16 0.04 1.69 0.95 2.23
Cash Interest Paid		 0.01 0.01 0.01 0.05 0.20 0.12 0.10 0.04 0.06 0.03 0.34
Cash Income Taxes Paid		 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for BioLargo

This table details how cash moves in and out of BioLargo's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.53 1.30 0.80 0.43 -1.92 -1.44 -1.26 0.91 1.08 -1.17 0.24
Net Cash From Operating Activities		 -0.84 -0.00 0.48 -0.15 -1.62 -1.92 -1.83 -2.12 -2.76 -1.59 -2.92
Net Cash From Continuing Operating Activities		 -0.81 -0.00 0.48 -0.15 -1.62 -1.92 -1.83 -2.12 -2.76 -1.59 -2.92
Net Income / (Loss) Continuing Operations		 -1.51 -1.02 -0.78 -0.78 -1.06 -1.73 -1.92 -1.88 -7.24 -4.14 -3.41
Consolidated Net Income / (Loss)		 -1.51 -1.02 -0.78 -0.78 -1.06 -1.73 -1.92 -1.88 -7.24 -4.14 -3.41
Depreciation Expense		 0.05 0.01 0.04 0.04 0.04 0.04 0.04 0.04 0.03 0.03 0.03
Amortization Expense		 0.03 0.08 0.01 0.04 0.03 0.03 0.07 0.08 0.11 0.19 0.14
Non-Cash Adjustments To Reconcile Net Income		 0.91 1.14 0.58 0.58 0.32 0.94 0.72 0.67 4.68 1.24 0.71
Changes in Operating Assets and Liabilities, net		 -0.28 -0.21 0.63 -0.03 -0.95 -1.19 -0.74 -1.03 -0.33 1.09 -0.40
Net Cash From Investing Activities		 -0.21 -0.15 -0.86 -0.36 -0.04 -0.06 0.00 0.19 0.26 -0.01 -0.03
Net Cash From Continuing Investing Activities		 -0.21 -0.15 -0.86 -0.36 -0.04 -0.06 0.00 0.19 0.26 -0.01 -0.03
Purchase of Property, Plant & Equipment		 -0.21 -0.15 -0.86 -0.36 -0.04 0.03 0.00 - -0.03 -0.01 -0.03
Net Cash From Financing Activities		 0.51 0.76 1.08 1.00 0.76 1.59 0.87 2.83 3.57 0.95 3.19
Net Cash From Continuing Financing Activities		 0.51 1.56 1.08 1.00 -0.23 0.54 0.57 2.83 3.57 0.42 3.19
Repayment of Debt		 -0.01 0.12 -0.01 -0.00 -0.00 -0.00 -0.00 -0.01 -0.01 0.04 -0.01
Issuance of Debt		 - - 0.00 - - 0.86 0.59 0.72 - -0.05 2.40
Issuance of Common Equity		 0.23 -0.25 0.53 0.64 -0.82 0.25 -0.02 - - 1.73 0.26
Other Financing Activities, net		 0.00 1.69 0.56 0.36 0.59 -0.57 0.00 2.12 1.43 -1.31 0.55
Cash Interest Paid		 0.01 0.02 0.01 0.00 -0.00 0.02 0.04 - 0.21 0.10 0.13
Cash Income Taxes Paid		 -0.01 - 0.00 0.01 -0.01 - 0.00 - - - 0.00

Annual Balance Sheets for BioLargo

This table presents BioLargo's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.91 2.11 1.50 3.19 3.62 4.94 3.02 4.86 8.21 11 8.31
Total Current Assets		 1.89 2.02 1.16 0.96 1.07 1.51 1.80 3.15 6.36 7.14 5.11
Cash & Equivalents		 1.76 1.91 0.99 0.66 0.66 0.72 0.96 1.85 3.54 3.55 3.88
Accounts Receivable		 0.04 0.07 0.09 0.26 0.36 0.48 0.51 1.06 2.61 3.17 0.62
Inventories, net		 0.04 0.03 0.05 0.03 0.02 0.28 0.24 0.12 0.15 0.33 0.31
Prepaid Expenses		 0.05 0.00 0.02 0.02 0.04 0.03 0.09 0.12 0.06 0.09 0.31
Plant, Property, & Equipment, net		 0.00 0.06 0.11 0.13 0.10 0.06 0.06 0.29 0.66 1.74 1.64
Total Noncurrent Assets		 0.02 0.04 0.23 2.10 2.46 3.38 1.16 1.42 1.18 1.55 1.47
Noncurrent Note & Lease Receivables		 - - - - - - - - 0.00 0.45 0.34
Other Noncurrent Operating Assets		 0.02 0.04 0.23 0.21 0.57 1.16 1.11 1.39 1.16 1.09 1.13
Total Liabilities & Shareholders' Equity		 1.91 2.11 1.50 3.19 3.62 4.94 3.02 4.86 8.21 11 8.31
Total Liabilities		 0.77 2.88 4.91 4.31 5.80 5.18 2.09 2.85 4.00 4.46 6.79
Total Current Liabilities		 0.46 1.15 4.22 2.49 4.35 3.54 1.37 1.58 2.71 2.65 5.06
Short-Term Debt		 0.00 0.61 5.25 2.20 5.06 2.33 0.31 0.00 0.30 0.55 1.48
Accounts Payable		 0.32 0.20 0.22 0.50 1.00 1.05 1.35 2.12 1.49 1.81 2.80
Current Deferred Revenue		 - - - - 0.04 0.05 0.09 0.02 - 0.00 0.28
Other Current Liabilities		 0.00 0.26 -1.26 -0.21 0.13 0.11 0.10 0.10 0.41 0.19 0.31
Total Noncurrent Liabilities		 0.31 1.73 0.69 1.82 0.93 1.63 0.72 1.27 1.29 1.81 1.72
Long-Term Debt		 3.25 5.25 1.54 1.29 - 0.51 0.37 0.50 0.29 0.53 0.60
Capital Lease Obligations		 - - - 0.00 - - - 0.77 - 0.36 0.26
Other Noncurrent Operating Liabilities		 -2.94 -3.52 0.00 0.53 0.93 1.13 0.35 - 1.00 0.92 0.86
Total Equity & Noncontrolling Interests		 1.14 -0.77 -3.41 -1.12 -2.18 -0.24 0.93 2.01 4.20 6.06 1.53
Total Preferred & Common Equity		 0.35 -1.33 -4.10 -1.50 -2.15 3.86 4.65 4.88 6.84 8.85 4.04
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.35 -1.33 -4.10 -1.50 -2.15 3.86 4.65 4.88 6.84 8.85 4.04
Common Stock		 84 91 97 110 121 136 144 149 154 159 166
Retained Earnings		 -84 -92 -101 -112 -123 -132 -139 -144 -147 -150 -161
Accumulated Other Comprehensive Income / (Loss)		 -0.04 -0.08 -0.06 -0.09 -0.10 -0.10 -0.12 -0.15 -0.28 -0.18 -0.21
Noncontrolling Interest		 0.79 0.55 0.70 0.37 -0.03 -4.09 -3.72 -2.87 -2.64 -2.80 -2.52

Quarterly Balance Sheets for BioLargo

This table presents BioLargo's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 6.55 9.82 10 10 11 12 9.13 8.57
Total Current Assets		 4.69 7.18 7.11 7.39 7.22 9.19 5.78 5.45
Cash & Equivalents		 3.04 4.34 4.77 3.88 2.56 3.47 4.55 4.12
Accounts Receivable		 1.45 2.47 2.10 3.21 4.21 1.74 0.76 0.73
Inventories, net		 0.12 0.25 0.18 0.24 0.37 0.44 0.41 0.29
Prepaid Expenses		 0.07 0.12 0.07 0.07 0.08 0.05 0.06 0.30
Plant, Property, & Equipment, net		 0.60 1.49 1.81 1.81 1.70 1.66 1.66 1.64
Total Noncurrent Assets		 1.26 1.16 1.13 1.10 1.59 1.65 1.69 1.40
Noncurrent Note & Lease Receivables		 - - - - 0.52 0.59 0.48 0.31
Other Noncurrent Operating Assets		 1.24 1.14 1.11 1.09 1.06 1.04 1.19 1.09
Total Liabilities & Shareholders' Equity		 6.55 9.82 10 10 11 12 9.13 8.57
Total Liabilities		 2.73 4.67 4.16 4.32 5.42 6.44 5.92 8.75
Total Current Liabilities		 1.74 3.40 3.01 3.20 3.37 4.08 3.45 4.93
Short-Term Debt		 0.07 0.23 0.00 0.00 0.81 1.12 1.12 1.51
Accounts Payable		 0.89 1.74 3.94 4.40 3.51 4.04 2.92 2.59
Current Deferred Revenue		 0.00 - 0.09 0.02 - - - 0.32
Other Current Liabilities		 0.10 1.42 0.11 0.11 0.19 0.19 0.23 0.33
Total Noncurrent Liabilities		 0.99 1.27 1.15 1.12 2.05 2.36 2.46 3.82
Long-Term Debt		 0.29 0.28 0.18 0.18 0.81 1.17 1.20 2.78
Capital Lease Obligations		 - - 0.97 0.94 0.90 0.87 0.97 0.23
Other Noncurrent Operating Liabilities		 0.70 0.99 - - 0.34 0.32 0.30 0.81
Total Equity & Noncontrolling Interests		 3.82 5.15 5.89 5.98 5.09 6.06 3.22 -0.19
Total Preferred & Common Equity		 7.07 8.12 6.00 8.58 7.61 8.76 6.58 1.79
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 7.07 8.12 6.00 8.58 7.61 8.76 6.58 1.79
Common Stock		 154 156 154 157 158 161 165 166
Retained Earnings		 -146 -148 -148 -148 -151 -152 -158 -164
Accumulated Other Comprehensive Income / (Loss)		 -0.16 -0.18 -0.24 -0.23 -0.20 -0.20 -0.20 -0.21
Noncontrolling Interest		 -3.25 -2.97 -0.11 -2.60 -2.52 -2.70 -3.37 -1.97

Annual Metrics And Ratios for BioLargo

This table displays calculated financial ratios and metrics derived from BioLargo's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 89,915,980.00 102,364,539.00 132,292,528.00 163,916,660.00 222,395,857.00 257,726,382.00 275,417,050.00 289,500,358.00 301,179,163.00 313,762,657.00
DEI Adjusted Shares Outstanding		 0.00 89,915,980.00 102,364,539.00 132,292,528.00 163,916,660.00 222,395,857.00 257,726,382.00 275,417,050.00 289,500,358.00 301,179,163.00 313,762,657.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -0.09 -0.09 -0.08 -0.07 -0.04 -0.03 -0.02 -0.01 -0.01 -0.04
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 14.38% 120.33% 83.56% 428.68% -31.78% 30.68% 4.07% 132.48% 107.85% 45.37% -56.32%
EBITDA Growth		 3.25% 28.94% -15.07% -28.86% 11.66% -89.99% -13.02% 22.10% 15.71% 5.21% -251.00%
EBIT Growth		 -20.37% -21.14% -16.40% -8.65% -3.58% -14.94% 10.56% 22.79% 11.38% 5.33% -244.20%
NOPAT Growth		 -23.30% -18.02% -19.48% -8.75% -4.43% -13.25% 10.62% 20.48% 15.03% 5.44% -242.99%
Net Income Growth		 -35.77% -59.04% -18.24% -12.04% -6.96% 15.21% 28.93% 25.56% 9.43% 6.48% -249.41%
EPS Growth		 -20.00% -50.00% -11.11% 10.00% 11.11% 37.50% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -9.58% -97.57% -15.13% 9.17% -13.65% 6.06% 5.22% 29.85% 14.37% -35.56% -158.80%
Free Cash Flow Firm Growth		 -142.69% 31.42% 38.02% -87.39% 17.16% -62.03% 51.34% -44.32% 6.76% -30.50% -22.48%
Invested Capital Growth		 984.38% 21.19% -51.61% 11.05% -48.45% 107.26% -93.21% 498.39% 119.68% 141.78% -97.82%
Revenue Q/Q Growth		 -10.27% 4.11% 34.41% 0.00% 0.00% 0.00% -21.57% 47.06% 22.84% -3.87% -28.12%
EBITDA Q/Q Growth		 23.15% 15.69% -30.81% -214.58% -201.37% -72.70% 21.52% -35.03% 9.43% -21.49% -17.67%
EBIT Q/Q Growth		 4.10% -7.09% -6.27% 0.00% 0.00% -24.56% 21.56% -34.93% 7.68% -19.27% -18.32%
NOPAT Q/Q Growth		 1.77% -6.86% -5.33% 0.00% 0.00% -4.18% 2.92% 6.05% 8.20% -16.39% -19.21%
Net Income Q/Q Growth		 -3.58% -15.94% -1.31% 0.00% 0.00% 0.00% 2.85% 6.94% 7.70% -19.59% -18.86%
EPS Q/Q Growth		 14.29% -12.50% -11.11% 10.00% -14.29% 16.67% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -14.67% -11.33% -7.19% 8.67% -9.97% 8.88% -3.66% 26.89% -1.85% -148.14% 3.78%
Free Cash Flow Firm Q/Q Growth		 -86.54% 42.68% 20.67% -295.84% -41.66% -47.99% 25.16% -65.39% 20.89% -90.42% 16.95%
Invested Capital Q/Q Growth		 1,064.09% -8.92% -43.15% 419.94% -71.14% -16.35% -90.89% 0.00% -3.15% 109.18% -91.73%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 51.35% 62.34% 37.40% 45.53% 49.22% 50.49% 43.58% 48.56% 50.32% 44.17% 43.86%
EBITDA Margin		 -2,557.47% -824.81% -517.05% -126.03% -163.19% -237.25% -257.65% -86.34% -35.01% -22.83% -183.48%
Operating Margin		 -3,277.49% -1,755.52% -1,142.64% -235.04% -359.81% -311.80% -267.80% -91.60% -37.45% -24.36% -191.31%
EBIT Margin		 -3,199.79% -1,759.21% -1,115.50% -229.25% -348.09% -306.17% -263.14% -87.39% -37.26% -24.26% -191.23%
Profit (Net Income) Margin		 -3,979.43% -2,872.35% -1,850.19% -392.08% -614.72% -398.85% -272.38% -87.22% -38.00% -24.45% -195.61%
Tax Burden Percent		 100.00% 100.00% 93.09% 112.27% 99.45% 98.87% 100.00% 98.79% 100.00% 100.00% 100.00%
Interest Burden Percent		 124.37% 163.28% 178.18% 152.33% 177.57% 131.76% 103.51% 101.03% 102.00% 100.77% 102.29%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -251.52% -119.02% -174.91% -276.38% -361.95% -392.18% -486.63% -871.36% -270.32% -108.84% -516.44%
ROIC Less NNEP Spread (ROIC-NNEP)		 -523.95% -289.08% -296.72% -435.96% -591.13% -563.67% -829.98% -740.56% -195.24% -52.71% -246.93%
Return on Net Nonoperating Assets (RNNOA)		 -1,103.99% -4,231.72% 631.79% 748.40% 1,054.65% 1,195.49% -1,488.73% 522.72% 120.70% 24.09% 115.78%
Return on Equity (ROE)		 -1,355.50% -4,350.75% 456.88% 472.02% 692.70% 803.31% -1,975.36% -348.64% -149.62% -84.75% -400.66%
Cash Return on Invested Capital (CROIC)		 -222.85% -138.18% -105.35% -286.85% -298.01% -461.99% -312.06% -1,014.09% -345.19% -191.80% -324.98%
Operating Return on Assets (OROA)		 -376.09% -245.85% -319.00% -267.21% -190.36% -173.91% -167.23% -130.49% -69.77% -46.09% -157.77%
Return on Assets (ROA)		 -467.72% -401.41% -529.11% -457.00% -336.17% -226.56% -173.11% -130.24% -71.16% -46.45% -161.38%
Return on Common Equity (ROCE)		 182.95% 11,409.59% 593.53% 583.26% 765.27% -567.14% -24,086.35% -1,128.70% -282.29% -129.67% -681.31%
Return on Equity Simple (ROE_SIMPLE)		 -1,443.18% 609.31% 232.63% 714.97% 531.35% -251.43% -148.16% -105.21% -67.91% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.93 -3.45 -4.13 -4.49 -4.69 -5.31 -4.74 -3.77 -3.21 -3.03 -10
NOPAT Margin		 -2,294.24% -1,228.86% -799.85% -164.53% -251.86% -218.26% -187.46% -64.12% -26.21% -17.05% -133.92%
Net Nonoperating Expense Percent (NNEP)		 272.43% 170.06% 121.81% 159.58% 229.18% 171.49% 343.35% -130.80% -75.08% -56.13% -269.51%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -66.92% -40.45% -269.25%
Cost of Revenue to Revenue		 48.65% 37.66% 186.24% 54.47% 50.78% 49.51% 56.42% 51.44% 49.68% 55.83% 56.14%
SG&A Expenses to Revenue		 2,783.72% 1,321.35% 858.33% 194.79% 329.93% 307.28% 243.86% 114.40% 65.89% 52.32% 151.55%
R&D to Revenue		 536.56% 491.61% 315.89% 63.01% 79.10% 55.02% 54.01% 22.42% 18.66% 16.21% 33.39%
Operating Expenses to Revenue		 3,328.84% 1,817.85% 1,180.04% 235.04% 409.03% 362.29% 311.38% 140.16% 87.77% 68.53% 235.17%
Earnings before Interest and Taxes (EBIT)		 -4.08 -4.95 -5.76 -6.25 -6.48 -7.45 -6.66 -5.14 -4.56 -4.31 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.26 -2.32 -2.67 -3.44 -3.04 -5.77 -6.52 -5.08 -4.28 -4.06 -14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 122.62 0.00 0.00 0.00 0.00 7.61 11.98 11.31 7.25 6.47 14.58
Price to Tangible Book Value (P/TBV)		 122.62 0.00 0.00 0.00 0.00 17.20 11.98 11.31 7.25 6.47 14.58
Price to Revenue (P/Rev)		 338.10 279.32 78.42 12.56 20.00 12.08 22.03 9.38 4.06 3.22 7.59
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 17.30 26.11 30.51 21.93 47.23 14.97 416.94 69.70 27.01 13.28 637.99
Enterprise Value to Revenue (EV/Rev)		 355.91 295.35 91.01 13.74 22.36 11.24 20.43 8.79 3.60 2.94 7.07
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 2.84 -7.61 -1.99 -3.11 -2.32 -12.09 0.73 0.63 0.14 0.24 1.53
Long-Term Debt to Equity		 2.84 -6.82 -0.45 -1.15 0.00 -2.16 0.39 0.63 0.07 0.15 0.56
Financial Leverage		 2.11 14.64 -2.13 -1.72 -1.78 -2.12 1.79 -0.71 -0.62 -0.46 -0.47
Leverage Ratio		 2.90 10.84 -0.86 -1.03 -2.06 -3.55 11.41 2.68 2.10 1.82 2.48
Compound Leverage Factor		 3.60 17.70 -1.54 -1.57 -3.66 -4.67 11.81 2.70 2.14 1.84 2.54
Debt to Total Capital		 73.99% 115.13% 200.89% 147.50% 175.59% 109.02% 42.19% 38.73% 12.29% 19.20% 60.49%
Short-Term Debt to Total Capital		 0.00% 11.98% 155.34% 92.85% 175.59% 89.56% 19.45% 0.00% 6.26% 7.36% 38.27%
Long-Term Debt to Total Capital		 73.99% 103.15% 45.55% 54.65% 0.00% 19.46% 22.74% 38.73% 6.03% 11.83% 22.22%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 18.00% 10.90% 20.57% 15.78% -0.94% -157.12% -230.48% -87.36% -55.15% -37.29% -65.15%
Common Equity to Total Capital		 8.02% -26.03% -121.46% -63.28% -74.65% 148.10% 288.29% 148.63% 142.85% 118.09% 104.66%
Debt to EBITDA		 -0.99 -2.53 -2.54 -1.01 -1.67 -0.49 -0.10 -0.25 -0.14 -0.35 -0.16
Net Debt to EBITDA		 -0.45 -1.70 -2.17 -0.82 -1.45 -0.36 0.05 0.12 0.69 0.52 0.11
Long-Term Debt to EBITDA		 -0.99 -2.26 -0.58 -0.38 0.00 -0.09 -0.06 -0.25 -0.07 -0.22 -0.06
Debt to NOPAT		 -1.11 -1.70 -1.64 -0.78 -1.08 -0.54 -0.14 -0.34 -0.18 -0.47 -0.22
Net Debt to NOPAT		 -0.51 -1.14 -1.40 -0.63 -0.94 -0.39 0.07 0.16 0.93 0.70 0.15
Long-Term Debt to NOPAT		 -1.11 -1.52 -0.37 -0.29 0.00 -0.10 -0.08 -0.34 -0.09 -0.29 -0.08
Altman Z-Score		 -34.04 -51.67 -104.57 -50.54 -50.38 -38.98 -54.69 -31.64 -17.47 -11.35 -26.91
Noncontrolling Interest Sharing Ratio		 113.50% 362.24% -29.91% -23.57% -10.48% 170.60% -1,119.34% -223.74% -88.67% -53.00% -70.05%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.11 1.75 0.27 0.38 0.24 0.42 1.31 2.00 2.35 2.70 1.01
Quick Ratio		 3.92 1.71 0.26 0.37 0.23 0.34 1.07 1.85 2.27 2.54 0.89
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.85 -4.01 -2.49 -4.66 -3.86 -6.25 -3.04 -4.39 -4.09 -5.34 -6.54
Operating Cash Flow to CapEx		 0.00% -6,008.16% -14,772.41% -6,708.62% -12,634.29% -18,060.87% -18,747.62% -1,019.19% -494.77% -259.60% 0.00%
Free Cash Flow to Firm to Interest Expense		 -5.88 -1.28 -0.64 -1.03 -0.77 -2.64 -13.00 -82.85 0.00 -75.25 -12.12
Operating Cash Flow to Interest Expense		 -1.89 -1.19 -1.11 -0.86 -0.88 -1.76 -16.82 -52.11 0.00 -45.15 -15.36
Operating Cash Flow Less CapEx to Interest Expense		 -1.89 -1.21 -1.12 -0.87 -0.89 -1.77 -16.91 -57.23 0.00 -62.55 -14.56
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.12 0.14 0.29 1.17 0.55 0.57 0.64 1.49 1.87 1.90 0.83
Accounts Receivable Turnover		 5.42 5.14 6.37 15.54 6.08 5.80 5.08 7.46 6.65 6.15 4.11
Inventory Turnover		 1.97 2.95 21.73 37.15 45.00 8.22 5.51 16.77 44.51 41.10 13.62
Fixed Asset Turnover		 0.00 0.00 6.13 23.22 16.84 31.38 41.83 33.82 25.77 14.79 4.59
Accounts Payable Turnover		 0.15 0.40 4.53 4.10 1.26 1.18 1.19 1.75 3.37 6.01 1.89
Days Sales Outstanding (DSO)		 67.30 71.04 57.29 23.48 60.02 62.96 71.89 48.91 54.85 59.33 88.91
Days Inventory Outstanding (DIO)		 185.09 123.90 16.80 9.83 8.11 44.41 66.20 21.76 8.20 8.88 26.80
Days Payable Outstanding (DPO)		 2,410.87 905.09 80.54 89.04 289.10 309.98 306.34 208.97 108.31 60.69 193.26
Cash Conversion Cycle (CCC)		 -2,158.48 -710.15 -6.45 -55.73 -220.98 -202.61 -168.25 -138.29 -45.26 7.52 -77.55
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.62 3.18 1.54 1.71 0.88 1.83 0.12 0.74 1.63 3.94 0.09
Invested Capital Turnover		 0.11 0.10 0.22 1.68 1.44 1.80 2.60 13.59 10.31 6.38 3.86
Increase / (Decrease) in Invested Capital		 2.92 0.56 -1.64 0.17 -0.83 0.95 -1.70 0.62 0.89 2.31 -3.86
Enterprise Value (EV)		 45 83 47 37 42 27 52 52 44 52 55
Market Capitalization		 43 79 40 34 37 29 56 55 50 57 59
Book Value per Share		 $0.00 ($0.01) ($0.04) ($0.01) ($0.01) $0.02 $0.02 $0.02 $0.02 $0.03 $0.01
Tangible Book Value per Share		 $0.00 ($0.01) ($0.04) ($0.03) ($0.02) $0.01 $0.02 $0.02 $0.02 $0.03 $0.01
Total Capital		 4.39 5.09 3.38 2.36 2.88 2.61 1.61 3.28 4.79 7.50 3.86
Total Debt		 3.25 5.86 6.79 3.49 5.06 2.84 0.68 1.27 0.59 1.44 2.34
Total Long-Term Debt		 3.25 5.25 1.54 1.29 0.00 0.51 0.37 1.27 0.29 0.89 0.86
Net Debt		 1.48 3.95 5.80 2.83 4.41 2.06 -0.33 -0.61 -2.97 -2.12 -1.55
Capital Expenditures (CapEx)		 0.00 0.06 0.03 0.06 0.04 0.02 0.02 0.27 0.48 1.24 -0.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.33 -0.44 1.20 0.00 1.12 -0.42 -0.22 -0.27 0.41 1.49 -2.35
Debt-free Net Working Capital (DFNWC)		 1.43 1.47 2.19 0.66 1.78 0.29 0.74 1.58 3.95 5.04 1.53
Net Working Capital (NWC)		 1.43 0.86 -3.06 -1.54 -3.29 -2.04 0.43 1.58 3.65 4.49 0.05
Net Nonoperating Expense (NNE)		 2.15 4.62 5.42 6.21 6.75 4.39 2.15 1.36 1.44 1.32 4.79
Net Nonoperating Obligations (NNO)		 1.48 3.95 4.95 2.83 3.06 2.06 -0.81 -1.27 -2.57 -2.12 -1.44
Total Depreciation and Amortization (D&A)		 0.82 2.63 3.09 2.82 3.44 1.68 0.14 0.06 0.28 0.26 0.60
Debt-free, Cash-free Net Working Capital to Revenue		 -260.19% -155.89% 232.75% 0.15% 60.18% -17.35% -8.73% -4.66% 3.38% 8.40% -30.32%
Debt-free Net Working Capital to Revenue		 1,121.76% 523.62% 424.61% 24.16% 95.38% 12.09% 29.28% 26.80% 32.31% 28.35% 19.69%
Net Working Capital to Revenue		 1,121.76% 306.62% -592.64% -56.31% -176.73% -83.84% 16.87% 26.80% 29.86% 25.25% 0.66%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.06) ($0.09) ($0.10) ($0.09) ($0.08) ($0.05) ($0.03) ($0.02) ($0.02) ($0.01) ($0.04)
Adjusted Weighted Average Basic Shares Outstanding		 84.11M 87.94M 98.94M 122.00M 152.09M 195.99M 247.20M 268.30M 285.96M 298.12M 306.95M
Adjusted Diluted Earnings per Share		 ($0.06) ($0.09) ($0.10) ($0.09) ($0.08) ($0.05) ($0.03) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 86.27M 94.95M 105.11M 143.10M 172.34M 238.78M 262.72M 283.19M 295.55M 301.30M 319.75M
Adjusted Basic & Diluted Earnings per Share		 ($0.06) ($0.09) ($0.10) ($0.09) ($0.08) ($0.05) ($0.03) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 86.27M 94.95M 105.11M 143.10M 172.34M 238.78M 262.72M 283.19M 295.55M 301.30M 319.75M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.93 -3.45 -4.13 -4.49 -4.69 -5.31 -4.51 -3.64 -2.93 -3.03 -10
Normalized NOPAT Margin		 -2,294.24% -1,228.86% -799.85% -164.53% -251.86% -218.26% -178.00% -61.78% -23.96% -17.05% -133.79%
Pre Tax Income Margin		 -3,979.43% -2,872.35% -1,987.60% -349.23% -618.11% -403.41% -272.38% -88.29% -38.00% -24.45% -195.61%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.10 -1.58 -1.49 -1.39 -1.29 -3.15 -28.46 -97.02 0.00 -60.76 -27.50
NOPAT to Interest Expense		 -2.94 -1.10 -1.07 -0.99 -0.93 -2.24 -20.28 -71.19 0.00 -42.70 -19.26
EBIT Less CapEx to Interest Expense		 -4.10 -1.60 -1.50 -1.40 -1.30 -3.16 -28.55 -102.13 0.00 -78.15 -26.69
NOPAT Less CapEx to Interest Expense		 -2.94 -1.12 -1.08 -1.01 -0.94 -2.25 -20.37 -76.30 0.00 -60.09 -18.45
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% -0.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for BioLargo

This table displays calculated financial ratios and metrics derived from BioLargo's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 288,073,533.00 289,500,358.00 295,552,937.00 296,839,523.00 300,619,329.00 301,179,163.00 301,303,131.00 302,840,771.00 308,989,058.00 313,762,657.00 319,750,855.00
DEI Adjusted Shares Outstanding		 288,073,533.00 289,500,358.00 295,552,937.00 296,839,523.00 300,619,329.00 301,179,163.00 301,303,131.00 302,840,771.00 308,989,058.00 313,762,657.00 319,750,855.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 -0.01 -0.01
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 78.13% 108.49% 27.20% 246.75% 62.84% -16.38% -31.32% -44.62% -74.65% -83.14% -65.89%
EBITDA Growth		 -67.55% 32.48% -71.50% 52.55% 32.03% -77.45% -141.41% -140.63% -608.76% -130.03% -78.77%
EBIT Growth		 -70.97% 27.19% -71.08% 50.10% 30.97% -68.67% -143.25% -131.62% -576.72% -134.29% -77.21%
NOPAT Growth		 -62.99% 28.88% -59.96% 42.91% 30.97% -60.58% -144.04% -102.47% -576.72% -148.05% -72.07%
Net Income Growth		 -78.04% 27.56% -56.88% 52.03% 29.71% -69.80% -147.87% -141.28% -583.40% -139.15% -77.25%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 10.97% -104.88% 1,218.60% 89.82% -93.78% -95,700.00% -480.46% -1,302.65% -70.31% 17.01% -59.40%
Free Cash Flow Firm Growth		 -493.62% 1.01% -412.20% 77.45% 65.79% -116.14% -256.74% -1,257.98% -343.15% 130.42% 130.76%
Invested Capital Growth		 0.00% 119.68% 114.65% -20.10% 11.94% 141.78% 245.31% 291.56% -44.80% -97.82% -91.52%
Revenue Q/Q Growth		 84.79% 63.55% 8.92% 5.34% -13.22% -16.02% -10.54% -15.05% -60.28% -44.15% 81.01%
EBITDA Q/Q Growth		 0.81% 36.55% 22.11% 3.19% -42.06% -65.66% -5.96% 3.50% -318.43% 46.23% 17.65%
EBIT Q/Q Growth		 1.41% 33.96% 24.83% -1.97% -36.38% -61.36% -8.41% 2.91% -298.45% 44.14% 18.00%
NOPAT Q/Q Growth		 1.41% 34.48% 24.23% -16.64% -19.21% -52.40% -15.15% 3.22% -298.45% 44.14% 20.12%
Net Income Q/Q Growth		 7.26% 32.36% 24.02% -0.65% -35.90% -63.40% -10.91% 2.03% -284.91% 42.82% 17.79%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 43.67% 99.76% 24,150.00% -131.39% -972.85% -18.27% 4.49% -15.74% -30.26% 42.37% -83.46%
Free Cash Flow Firm Q/Q Growth		 -84.63% 42.26% 29.62% 69.94% -180.03% -264.83% -16.16% -14.43% 8.62% 125.04% 17.46%
Invested Capital Q/Q Growth		 18.27% -3.15% -32.58% 3.46% 65.70% 109.18% -3.70% 17.31% -76.64% -91.73% 274.42%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 53.71% 47.83% 47.18% 42.62% 39.58% 47.84% 45.52% 51.17% 33.73% 20.29% 41.08%
EBITDA Margin		 -54.68% -21.21% -15.17% -13.94% -22.82% -45.02% -53.32% -60.57% -638.08% -614.29% -279.46%
Operating Margin		 -57.52% -23.04% -16.03% -17.75% -24.39% -44.25% -56.96% -64.89% -650.95% -651.14% -287.35%
EBIT Margin		 -57.52% -23.23% -16.03% -15.52% -24.39% -46.85% -56.78% -64.89% -650.95% -651.14% -294.98%
Profit (Net Income) Margin		 -56.44% -23.34% -16.28% -15.56% -24.36% -47.40% -58.76% -67.77% -656.75% -672.40% -305.38%
Tax Burden Percent		 97.35% 98.65% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.78% 101.87% 101.57% 100.26% 99.91% 101.17% 103.50% 104.44% 100.89% 103.27% 103.53%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -476.39% -166.34% -184.54% -163.24% -177.01% -197.72% -265.40% -228.39% -3,367.01% -1,757.76% -548.28%
ROIC Less NNEP Spread (ROIC-NNEP)		 -435.90% -149.93% -177.75% -159.02% -166.83% -172.11% -242.28% -208.89% -3,296.28% -1,682.69% -252.56%
Return on Net Nonoperating Assets (RNNOA)		 243.70% 92.69% 144.83% 118.38% 106.09% 78.64% 126.47% 111.21% 2,248.18% 788.97% 40.49%
Return on Equity (ROE)		 -232.69% -73.65% -39.71% -44.86% -70.92% -119.08% -138.93% -117.19% -1,118.83% -968.79% -507.80%
Cash Return on Invested Capital (CROIC)		 -615.01% -345.19% -495.74% -207.18% -157.31% -191.80% -265.51% -277.49% -538.90% -324.98% -382.07%
Operating Return on Assets (OROA)		 -87.50% -43.49% -25.79% -31.19% -53.53% -89.00% -90.97% -80.86% -723.67% -537.19% -173.53%
Return on Assets (ROA)		 -85.85% -43.71% -26.20% -31.27% -53.48% -90.04% -94.15% -84.45% -730.12% -554.74% -179.65%
Return on Common Equity (ROCE)		 -430.94% -138.95% -66.18% -59.89% -113.25% -182.19% -213.38% -144.69% -1,844.07% -1,647.40% -973.02%
Return on Equity Simple (ROE_SIMPLE)		 -71.24% 0.00% -60.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.08 -0.70 -0.53 -0.62 -0.74 -1.13 -1.30 -1.26 -5.03 -2.81 -2.24
NOPAT Margin		 -40.27% -16.13% -11.22% -12.43% -17.07% -30.98% -39.87% -45.42% -455.67% -455.80% -201.15%
Net Nonoperating Expense Percent (NNEP)		 -40.50% -16.41% -6.80% -4.21% -10.18% -25.61% -23.11% -19.51% -70.73% -75.07% -295.73%
Return On Investment Capital (ROIC_SIMPLE)		 - -14.71% -9.43% -8.85% -10.45% -15.10% -17.13% -13.68% -77.32% -72.70% -51.70%
Cost of Revenue to Revenue		 46.29% 52.17% 52.82% 57.38% 60.42% 52.16% 54.48% 48.83% 66.27% 79.71% 58.92%
SG&A Expenses to Revenue		 85.25% 51.88% 46.74% 47.95% 48.10% 70.61% 77.15% 96.80% 279.96% 557.31% 247.09%
R&D to Revenue		 25.97% 9.98% 16.47% 12.43% 15.86% 21.48% 24.20% 19.27% 55.76% 105.84% 81.35%
Operating Expenses to Revenue		 111.23% 70.87% 63.21% 60.37% 63.96% 92.09% 102.48% 116.06% 684.68% 671.43% 328.43%
Earnings before Interest and Taxes (EBIT)		 -1.54 -1.02 -0.76 -0.78 -1.06 -1.71 -1.86 -1.80 -7.18 -4.01 -3.29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.46 -0.93 -0.72 -0.70 -0.99 -1.65 -1.74 -1.68 -7.04 -3.78 -3.12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.79 7.25 12.98 12.77 8.23 6.47 11.00 7.26 8.08 14.58 29.11
Price to Tangible Book Value (P/TBV)		 6.79 7.25 12.98 12.77 8.23 6.47 11.00 7.26 8.08 14.58 29.11
Price to Revenue (P/Rev)		 4.82 4.06 7.95 4.56 3.82 3.22 5.14 4.52 4.92 7.59 9.26
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 24.97 27.01 89.67 64.13 34.61 13.28 21.39 13.59 46.64 637.99 156.56
Enterprise Value to Revenue (EV/Rev)		 4.22 3.60 7.44 4.34 3.53 2.94 4.98 4.31 4.49 7.07 8.98
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.09 0.14 0.10 0.20 0.19 0.24 0.50 0.52 1.02 1.53 -24.20
Long-Term Debt to Equity		 0.08 0.07 0.06 0.20 0.19 0.15 0.34 0.34 0.67 0.56 -16.11
Financial Leverage		 -0.56 -0.62 -0.81 -0.74 -0.64 -0.46 -0.52 -0.53 -0.68 -0.47 -0.16
Leverage Ratio		 1.71 2.10 1.89 1.67 1.72 1.82 1.99 1.89 2.11 2.48 3.89
Compound Leverage Factor		 1.73 2.14 1.92 1.68 1.72 1.85 2.06 1.97 2.13 2.56 4.03
Debt to Total Capital		 8.60% 12.29% 9.14% 16.32% 15.82% 19.20% 33.12% 34.26% 50.54% 60.49% 104.31%
Short-Term Debt to Total Capital		 1.58% 6.26% 4.13% 0.00% 0.00% 7.36% 10.67% 12.11% 17.17% 38.27% 34.88%
Long-Term Debt to Total Capital		 7.02% 6.03% 5.01% 16.32% 15.82% 11.83% 22.45% 22.15% 33.37% 22.22% 69.43%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -77.87% -55.15% -52.37% -1.56% -36.54% -37.29% -33.10% -29.24% -51.77% -65.15% -45.48%
Common Equity to Total Capital		 169.28% 142.85% 143.22% 85.24% 120.72% 118.09% 99.97% 94.98% 101.23% 104.66% 41.17%
Debt to EBITDA		 -0.08 -0.14 -0.11 -0.30 -0.34 -0.35 -0.50 -0.52 -0.27 -0.16 -0.29
Net Debt to EBITDA		 0.57 0.69 0.84 0.95 0.83 0.52 0.01 0.06 0.11 0.11 -0.03
Long-Term Debt to EBITDA		 -0.06 -0.07 -0.06 -0.30 -0.34 -0.22 -0.34 -0.34 -0.18 -0.06 -0.19
Debt to NOPAT		 -0.10 -0.18 -0.15 -0.39 -0.43 -0.47 -0.66 -0.71 -0.38 -0.22 -0.40
Net Debt to NOPAT		 0.77 0.93 1.13 1.24 1.06 0.70 0.02 0.08 0.15 0.15 -0.04
Long-Term Debt to NOPAT		 -0.08 -0.09 -0.08 -0.39 -0.43 -0.29 -0.45 -0.46 -0.25 -0.08 -0.27
Altman Z-Score		 -19.47 -16.04 -5.95 -7.64 -8.44 -10.54 -9.39 -9.95 -19.99 -22.61 -23.71
Noncontrolling Interest Sharing Ratio		 -85.20% -88.67% -66.67% -33.50% -59.69% -53.00% -53.58% -23.47% -64.82% -70.05% -91.62%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.70 2.35 2.11 2.36 2.31 2.70 2.14 2.25 1.67 1.01 1.10
Quick Ratio		 2.58 2.27 2.00 2.28 2.22 2.54 2.01 2.13 1.54 0.89 0.98
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.76 -1.59 -1.12 -0.34 -0.94 -3.44 -4.00 -4.58 -4.18 1.05 1.23
Operating Cash Flow to CapEx		 -407.80% -1.37% 55.74% -42.18% -4,153.85% 0.00% 0.00% 0.00% 0.00% -12,230.77% -9,115.63%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -72.59 0.00 -43.00 0.00 -29.04 0.00 6.54
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -124.62 0.00 -19.68 0.00 -19.16 0.00 -15.52
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -127.62 0.00 -19.68 0.00 -17.38 0.00 -15.69
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.52 1.87 1.61 2.01 2.20 1.90 1.60 1.25 1.11 0.83 0.59
Accounts Receivable Turnover		 6.85 6.65 6.88 10.71 7.93 6.15 4.88 7.32 5.44 4.11 2.27
Inventory Turnover		 40.42 44.51 34.50 58.80 57.22 41.10 29.65 24.75 17.85 13.62 9.79
Fixed Asset Turnover		 16.62 25.77 14.09 14.29 15.37 14.79 10.22 8.09 6.22 4.59 3.36
Accounts Payable Turnover		 5.55 3.37 2.98 3.82 3.89 6.01 3.50 1.92 1.58 1.89 1.06
Days Sales Outstanding (DSO)		 53.27 54.85 53.08 34.09 46.00 59.33 74.86 49.86 67.07 88.91 160.61
Days Inventory Outstanding (DIO)		 9.03 8.20 10.58 6.21 6.38 8.88 12.31 14.75 20.45 26.80 37.29
Days Payable Outstanding (DPO)		 65.81 108.31 122.42 95.53 93.71 60.69 104.30 189.97 231.24 193.26 344.13
Cash Conversion Cycle (CCC)		 -3.51 -45.26 -58.76 -55.24 -41.33 7.52 -17.14 -125.36 -143.72 -77.55 -146.23
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1.68 1.63 1.10 1.14 1.88 3.94 3.80 4.45 1.04 0.09 0.32
Invested Capital Turnover		 11.83 10.31 16.45 13.14 10.37 6.38 6.66 5.03 7.39 3.86 2.73
Increase / (Decrease) in Invested Capital		 1.68 0.89 0.59 -0.29 0.20 2.31 2.70 3.32 -0.84 -3.86 -3.47
Enterprise Value (EV)		 42 44 99 73 65 52 81 60 49 55 50
Market Capitalization		 48 50 105 77 71 57 84 64 53 59 52
Book Value per Share		 $0.02 $0.02 $0.03 $0.02 $0.03 $0.03 $0.03 $0.03 $0.02 $0.01 $0.01
Tangible Book Value per Share		 $0.02 $0.02 $0.03 $0.02 $0.03 $0.03 $0.03 $0.03 $0.02 $0.01 $0.01
Total Capital		 4.18 4.79 5.67 7.04 7.11 7.50 7.61 9.22 6.50 3.86 4.34
Total Debt		 0.36 0.59 0.52 1.15 1.12 1.44 2.52 3.16 3.29 2.34 4.53
Total Long-Term Debt		 0.29 0.29 0.28 1.15 1.12 0.89 1.71 2.04 2.17 0.86 3.01
Net Debt		 -2.70 -2.97 -3.84 -3.63 -2.77 -2.12 -0.06 -0.34 -1.28 -1.55 0.40
Capital Expenditures (CapEx)		 0.21 0.15 0.86 0.36 0.04 -0.03 0.00 0.00 -0.26 0.01 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.03 0.41 -0.33 -0.67 0.31 1.49 2.09 2.75 -1.11 -2.35 -2.10
Debt-free Net Working Capital (DFNWC)		 3.02 3.95 4.01 4.10 4.19 5.04 4.66 6.22 3.44 1.53 2.03
Net Working Capital (NWC)		 2.95 3.65 3.77 4.10 4.19 4.49 3.85 5.11 2.32 0.05 0.51
Net Nonoperating Expense (NNE)		 0.43 0.32 0.24 0.16 0.32 0.60 0.62 0.62 2.22 1.33 1.16
Net Nonoperating Obligations (NNO)		 -2.13 -2.57 -4.05 -4.76 -4.10 -2.12 -1.30 -1.61 -2.18 -1.44 0.51
Total Depreciation and Amortization (D&A)		 0.08 0.09 0.04 0.08 0.07 0.07 0.11 0.12 0.14 0.23 0.17
Debt-free, Cash-free Net Working Capital to Revenue		 -0.25% 3.38% -2.49% -3.97% 1.69% 8.40% 12.85% 19.59% -10.24% -30.32% -37.36%
Debt-free Net Working Capital to Revenue		 30.30% 32.31% 30.24% 24.37% 22.68% 28.35% 28.59% 44.29% 31.84% 19.69% 36.11%
Net Working Capital to Revenue		 29.64% 29.86% 28.47% 24.37% 22.68% 25.25% 23.61% 36.35% 21.51% 0.66% 9.14%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.01) $0.00 $0.00 $0.00 $0.00 ($0.01) $0.00 $0.00 ($0.02) ($0.01) ($0.01)
Adjusted Weighted Average Basic Shares Outstanding		 287.94M 285.96M 294.31M 296.44M 300.49M 298.12M 301.27M 303.20M 308.97M 306.95M 318.70M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 289.50M 295.55M 296.84M 300.62M 301.18M 301.30M 302.84M 308.99M 313.76M 319.75M 320.88M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 289.50M 295.55M 296.84M 300.62M 301.18M 301.30M 302.84M 308.99M 313.76M 319.75M 320.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.08 -0.70 -0.53 -0.62 -0.74 -1.13 -1.30 -1.26 -5.03 -2.81 -2.24
Normalized NOPAT Margin		 -40.27% -16.13% -11.22% -12.43% -17.07% -30.98% -39.87% -45.42% -455.67% -455.80% -201.15%
Pre Tax Income Margin		 -57.97% -23.66% -16.28% -15.56% -24.36% -47.40% -58.76% -67.77% -656.75% -672.40% -305.38%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -81.62 0.00 -19.96 0.00 -49.86 0.00 -17.49
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -57.13 0.00 -14.02 0.00 -34.90 0.00 -11.93
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -84.62 0.00 -19.96 0.00 -48.08 0.00 -17.66
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -60.13 0.00 -14.02 0.00 -33.13 0.00 -12.10
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

BioLargo’s latest quarter shows a mixed picture: revenue improved sharply from the prior quarter, but the company remained deeply unprofitable and continued to burn cash from operations. Q1 2026 revenue rose to $1.1 million from $616,000 in Q4 2025, yet operating expenses of $3.7 million still far exceeded gross profit of $458,000. That produced an operating loss of $3.2 million and a net loss of $3.4 million.

From a longer-term perspective, the business has been volatile but the trend in revenue has been down versus 2024. Quarterly revenue has generally moved lower over the last year, falling from $4.8 million in Q1 2024 and $5.0 million in Q2 2024 to $1.1 million in Q1 2026. Gross profit also compressed meaningfully, suggesting weaker sales mix, lower volume, or higher production costs.

Liquidity remains a key issue to watch. BioLargo ended Q1 2026 with $4.1 million in cash and $8.6 million in total assets, but liabilities were $8.8 million, leaving negative shareholder equity including noncontrolling interests. Operating cash flow was negative $2.9 million in the quarter, so the company is still dependent on external financing and balance-sheet actions to keep funding operations.

  • Revenue rebounded quarter over quarter: Q1 2026 revenue increased to $1.1 million from $616,000 in Q4 2025.
  • Gross profit improved from the prior quarter: gross profit rose to $458,000 from $125,000 in Q4 2025.
  • Cash on hand increased modestly: cash and equivalents were $4.1 million at the end of Q1 2026, up from $4.5 million in Q3 2025 but still supported by financing activity.
  • Debt levels remain elevated: total debt and lease obligations are still material relative to the company’s size, with $1.5 million of short-term debt and $2.8 million of long-term debt in Q1 2026.
  • The company is still investing in operations: R&D expense was $907,000 in Q1 2026, showing continued spending on development.
  • Operating losses remain large: Q1 2026 operating loss was $3.2 million, indicating the business model is not yet close to breakeven.
  • Net losses continue to exceed revenue: Q1 2026 net loss was $3.4 million, or about three times quarterly revenue.
  • Operating cash burn is substantial: the company used $2.9 million in cash from operations in Q1 2026.
  • Shareholder equity remains weak: total equity including noncontrolling interests was negative $187,000 in Q1 2026.
  • Recent financing has been needed to offset losses: Q1 2026 included $3.2 million of financing cash inflows, underscoring dependence on capital raises and debt.

Bottom line: BioLargo is showing some quarter-to-quarter improvement in revenue and gross profit, but the bigger four-year trend is still challenging. Sales have fallen sharply from 2024 levels, losses remain heavy, and cash generation from operations is negative. For retail investors, the main question is whether management can scale revenue enough to cover the company’s sizable overhead before further dilution or balance-sheet stress becomes a bigger issue.

07/18/26 07:08 AM ETAI Generated. May Contain Errors.

BioLargo Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BioLargo's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Over the last 10 years, BioLargo's net income changed from -$5.08 million in 2015 to -$15.19 million in 2025, a change of 199.2%.

BioLargo's total operating income in 2025 was -$14.86 million, based on the following breakdown:
  • Total Gross Profit: $3.41 million
  • Total Operating Expenses: $18.26 million

Over the last 10 years, BioLargo's total revenue changed from $127.58 thousand in 2015 to $7.77 million in 2025, a change of 5,986.3%.

BioLargo's total liabilities were at $6.79 million at the end of 2025, a 52.2% increase from 2024, and a 782.4% increase since 2015.

In the past 10 years, BioLargo's cash and equivalents has ranged from $655 thousand in 2018 to $3.88 million in 2025, and is currently $3.88 million as of their latest financial filing in 2025.

Over the last 10 years, BioLargo's book value per share changed from 0.00 in 2015 to 0.01 in 2025, a change of 207.1%.


Related Companies

Financial statements for NASDAQ:BLGO last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel
Central banks bought 710 tonnes - this fund pays monthly
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Elon’s message for America
Elon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...
Stansberry Research | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Ex-CIA Insider: “Prepare for a Mid-Term Meltdown”
Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...
Paradigm Press | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel